Full video transcriptClick to expand
Auto-generated transcript of @stevieleaabberton's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Just a little FYI.
- 0:03I don't know if you can notice but
- 0:05See how red my face is. I've just had my PT-141
- 0:10If you want to know what that does search it
- 0:14You can see how red my face is. It's hot to the touch
- 0:17It's red
- 0:19That is normal. That is okay. The same thing happens to me when I do MT2
- 0:25So the tanning injection
- 0:29She's she's very red this lasts for me
- 0:34Typically from anywhere to 30 minutes to an hour
- 0:38So if you have either of these or any some
- 0:43She map tides work differently for different people
- 0:47It's normal. It's fine. It's hot. It's annoying
- 0:52That's why some people take it at night. I like it doesn't last long enough for me that it bothers me
- 0:59But yeah, just thought I'd let you know
- 1:02It will go away. It passes. It's natural. It's normal. It's okay. I
- 1:08Think my chest is a little bit red too, but typically the face. I will add this is the only
- 1:18Side effect that I get from anything other than itching at the site
- 1:24Like this this PT-141's itching me at the moment. I've done it on my hip and
- 1:29She's itching but other than itching bruising and facial flushing
- 1:34These are the only side effects I have ever had from any of the peptides on one
- 1:41So yeah, I'm pretty okay with that to have some facial flushing a little bit of bruising itching
- 1:48Not too big of a deal for me
PT-141 facial flushing: normal side effect or warning sign?
Quick answer
Bremelanotide (PT-141) produces facial flushing through melanocortin receptor-mediated vasodilation, and this is one of its most consistently documented adverse effects in phase III clinical trials. However, nausea and transient blood pressure elevation are equally common and clinically significant reactions that this video does not address. Users should be screened for cardiovascular risk factors before use, and self-guided dosing decisions based on social media accounts are not a substitute for prescriber oversight.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
PT-141 (Bremelanotide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For PT-141 facial flushing: normal side effect or warning sign?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
PT-141 (Bremelanotide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "PT-141 facial flushing: normal side effect or warning sign?" from Stevielea Abberton. We read the clip as a Peptide social video fact-checks claim about PT-141 (Bremelanotide), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Bremelanotide (PT-141) produces facial flushing through melanocortin receptor-mediated vasodilation, and this is one of its most consistently documented adverse effects in phase III clinical trials.
The reason this review is not generic is the source wording and the canonical claim label "peptides this is a normal side effect it typically doesn t last long." In this clip, the useful excerpt is: "Just a little FYI." That wording changes the review because it points to PT-141 (Bremelanotide) safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against SCENESSE (afamelanotide implant) FDA Prescribing Information (2019), Afamelanotide for Erythropoietic Protoporphyria (2015), and Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (2012), plus the creator's own wording. PT-141 (Bremelanotide) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Bremelanotide (PT-141) produces facial flushing through melanocortin receptor-mediated vasodilation, and this is one of its most consistently documented adverse effects in phase III clinical trials.
FormBlends verdict
PT-141 (Bremelanotide) safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the PT-141 (Bremelanotide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Bremelanotide (PT-141) produces facial flushing through melanocortin receptor-mediated vasodilation, and this is one of its most consistently documented adverse effects in phase III clinical trials. However, nausea and transient blood pressure elevation are equally common and clinically significant reactions that this video does not address. Users should be screened for cardiovascular risk factors before use, and self-guided dosing decisions based on social media accounts are not a substitute for prescriber oversight.
- Facial flushing occurs in approximately 40% of bremelanotide users per RECONNECT phase III trial data (Kingsberg et al., 2019), making it the most common reported adverse effect.
- Nausea is equally prevalent at roughly 40% incidence and was the primary reason for discontinuation in trials, a fact absent from this video entirely.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- PT-141 (Bremelanotide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the PT-141 (Bremelanotide) guide, cost path, safety notes, and provider review before acting.
Review PT-141 (Bremelanotide)What You'll Learn
- Facial flushing occurs in approximately 40% of bremelanotide users per RECONNECT phase III trial data (Kingsberg et al., 2019), making it the most common reported adverse effect.
- Nausea is equally prevalent at roughly 40% incidence and was the primary reason for discontinuation in trials, a fact absent from this video entirely.
- Bremelanotide causes transient blood pressure increases averaging 6 mmHg systolic, and the FDA label contraindicates use in patients with cardiovascular disease or uncontrolled hypertension.
- Melanotan II is not FDA-approved for any use, has no regulated manufacturing or safety surveillance pathway, and is not clinically equivalent to bremelanotide despite sharing some receptor activity.
- Injection-site reactions including itching and bruising are documented, generally mild, and consistent with subcutaneous peptide administration across multiple compound classes.
- Personal side effect profiles vary significantly between individuals. One user's benign experience does not establish a population-level safety signal, and self-reassurance on social media is not a substitute for pre-treatment clinical screening.
- Flushing duration in trial data extended beyond one hour for a meaningful subset of participants, so her 30-60 minute personal window, while plausible, is not a reliable expectation for all users.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @stevieleaabberton actually say?
She showed her visibly red face on camera after injecting PT-141 (bremelanotide) and described facial flushing as a normal, temporary side effect, typically lasting 30 minutes to an hour for her. She also mentioned similar flushing with melanotan II, noted itching at the injection site and some bruising, and concluded that these were the only side effects she had personally experienced across peptide use. Her core message: "It will go away. It passes. It's natural. It's normal. It's okay."
She also suggested that searching what PT-141 does was sufficient to understand the drug, and that taking it at night is a strategy some people use to sleep through the flushing. She framed this as personal reassurance rather than medical guidance.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Stevielea Abberton · TikTok creator
5.5K views on this video
This is a normal side effect, it typically doesn’t last long so don’t panic. #sideeffects #pt141 #melo #facialflushing
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about facial flushing occurs in approximately 40% of bremelanotide users per?
Facial flushing occurs in approximately 40% of bremelanotide users per RECONNECT phase III trial data (Kingsberg et al., 2019), making it the most common reported adverse effect.
What does the video say about nausea?
Nausea is equally prevalent at roughly 40% incidence and was the primary reason for discontinuation in trials, a fact absent from this video entirely.
What does the video say about bremelanotide causes transient blood pressure increases averaging 6 mmhg systolic,?
Bremelanotide causes transient blood pressure increases averaging 6 mmHg systolic, and the FDA label contraindicates use in patients with cardiovascular disease or uncontrolled hypertension.
What does the video say about melanotan ii?
Melanotan II is not FDA-approved for any use, has no regulated manufacturing or safety surveillance pathway, and is not clinically equivalent to bremelanotide despite sharing some receptor activity.
What does the video say about injection-site reactions including itching?
Injection-site reactions including itching and bruising are documented, generally mild, and consistent with subcutaneous peptide administration across multiple compound classes.
What does the video say about personal side effect profiles vary significantly between individuals. one user's?
Personal side effect profiles vary significantly between individuals. One user's benign experience does not establish a population-level safety signal, and self-reassurance on social media is not a substitute for pre-treatment clinical screening.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Stevielea Abberton, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.